Gastroenterology
Volume 135, Issue 4 , Pages 1142-1154 , October 2008

A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults

  • April B.M. Grudell

      Affiliations

    • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota
    • ,
  • Seth Sweetser

      Affiliations

    • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota
    • ,
  • Michael Camilleri

      Affiliations

    • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota
    • Corresponding Author InformationAddress requests for reprints to: Michael Camilleri, MD, Mayo Clinic, Charlton 8-110, 200 First Street, SW, Rochester, Minnesota 55905
    • ,
  • Deborah J. Eckert

      Affiliations

    • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota
    • ,
  • Maria I. Vazquez-Roque

      Affiliations

    • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota
    • ,
  • Paula J. Carlson

      Affiliations

    • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota
    • ,
  • Duane D. Burton

      Affiliations

    • Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota
    • ,
  • Autumn E. Braddock

      Affiliations

    • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota
    • ,
  • Matthew M. Clark

      Affiliations

    • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota
    • ,
  • Karen M. Graszer

      Affiliations

    • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota
    • ,
  • Sarah A. Kalsy

      Affiliations

    • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota
    • ,
  • Alan R. Zinsmeister

      Affiliations

    • Department of Health Sciences Research, Division of Biostatistics, Mayo Clinic, Rochester, Minnesota

Received 10 April 2008 ,Accepted 2 July 2008.

References 

  1. Hainer V, Kabrnova K, Aldhoon B, et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann N Y Acad Sci. 2006;1083:252–269
  2. Berkowitz RI, Wadden TA, Tershakovec AM, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 2003;289:1805–1812
  3. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111–2120
  4. Hansen DL, Astrup A, Toubro S, et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity (Results from the European multi-centre STORM trial). Int J Obes. 2001;25:496–501
  5. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527–1531
  6. Rosmond R, Bouchard C, Bjorntorp P. A C-1291G polymorphism in the α2A adrenergic receptor gene (ADRA2A) promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. J Intern Med. 2002;251:252–257
  7. Serretti A, Lilli R, Lorenzi C, et al. Serotonin transporter gene (5-HTTLPR) and major psychoses. Mol Psychiatry. 2002;7:95–99
  8. Tsai SJ, Wang YC, Younger WYY, et al. Association analysis of polymorphisms in the promoter region of the α2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res. 2001;49:53–58
  9. Stein MB, Seedat S, Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl). 2006;187:68–72
  10. Murphy GM, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61:1163–1169
  11. Avissar S, Schreiber G. Ziskind-Somerfeld Research Award (The involvement of guanine nucleotide binding proteins in the pathogenesis and treatment of affective disorders). Biol Psychiatry. 1992;31:435–459
  12. Andersen G, Overgaard J, Albrechtsen A, et al. Studies of the association of the GNB3 825C>T polymorphism with components of the metabolic syndrome in white Danes. Diabetologia. 2006;49:75–82
  13. Baumgart D, Naber C, Haude M, et al. G protein β3 subunit 825T allele and enhanced coronary vasoconstriction on α(2)-adrenoceptor activation. Circ Res. 1999;85:965–969
  14. Garenc C, Pérusse L, Chagnon YC, et al. The α2-adrenergic receptor gene and body fat content and distribution: the HERITAGE Family Study. Mol Med. 2002;8:88–94
  15. Fuemmeler BF, Agurs-Collins TD, McClernon FJ, et al. Genes implicated in serotonergic and dopaminergic functioning predict BMI categories. Obesity. 2008;16:348–355
  16. Sookoian S, Gianotti TF, Gemma C, et al. Contribution of the functional 5-HTTLPR variant of the SLC6A4 gene to obesity risk in male adults. Obesity. 2008;16:488–491
  17. Hauner H, Meier M, Jöckel KH, et al. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein β3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics. 2003;13:453–459
  18. Vazquez Roque MI, Camilleri M, Clark MM, et al. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol. 2007;5:829–837
  19. Brownell K. The LEARN Program for weight management. 10th. Dallas: American Health Publishing Company; 2004;
  20. Marcus BH, Rakowski W, Rossi JS. Assessing motivational readiness and decision making for exercise. Health Psychol. 1992;11:257–261
  21. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370
  22. Swenson WM, Morse RM. The use of a self-administered alcoholism screening test (SAAST) in a medical center. Mayo Clin Proc. 1975;50:204–208
  23. Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct α (2) adrenoceptors and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut. 2004;53:829–837
  24. Andresen V, Camilleri M, Kim HJ, et al. Is there an association between GNβ3 C825T genotype and lower functional gastrointestinal disorders?. Gastroenterology. 2006;130:1985–1994
  25. Jensen MD, Kanaley JA, Roust LR, et al. Assessment of body composition with use of dual-energy x-ray absorptiometry: evaluation and comparison with other methods. Mayo Clin Proc. 1993;68:867–873
  26. Szarka LA, Camilleri M, Vella A, et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol. 2008;6:635–643
  27. Xu J, Chen JD. Peripheral mechanisms of sibutramine involving proximal gastric motility in dogs. Obesity. 2006;14:1363–1370
  28. Finer N, Ryan DH, Renz CL, et al. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab. 2006;8:206–213
  29. Serretti A, Benedetti F, Zanardi R, et al. The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatr. 2005;29:1074–1084
  30. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2002;123:425–432
  31. Ukkola O, Rankinen T, Weisnagel SJ, et al. Interactions among the α2-, β2-, and β3-adrenergic receptor genes and obesity-related phenotypes in the Quebec Family Study. Metabolism. 2000;49:1063–1070
  32. Dionne IJ, Turner AN, Tchernof A, et al. Identification of an interactive effect of β3- and α2b-adrenoceptor gene polymorphisms on fat mass in Caucasian women. Diabetes. 2001;50:91–95
  33. Lima JJ, Feng H, Duckworth L, et al. Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism. 2007;56:757–765
  34. Wellman PJ. Norepinephrine and the control of food intake. Nutrition. 2000;16:837–842
  35. Jackson HC, Bearham MC, Hutchins LJ, et al. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol. 1997;121:1613–1618
  36. Ritter S, Dinh TT, Li AJ. Hindbrain catecholamine neurons control multiple glucoregulatory responses. Physiol Behav. 2006;89:490–500
  37. Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res. 2006;53:482–491
  38. Deupree JD, Smith SD, Kratochvil CJ, et al. Possible involvement of α-2A adrenergic receptors in attention deficit hyperactivity disorder: radioligand binding and polymorphism studies. Am J Med Genet B Neuropsychiatr Genet. 2006;141:877–884
  39. Polanczyk G, Zeni C, Genro JP, et al. Association of the adrenergic α2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64:218–224
  40. Wang YC, Bai YM, Chen JY, et al. Polymorphism of the adrenergic receptor α2a-1291C>G genetic variation and clozapine-induced weight gain. J Neural Transm. 2005;112:1463–1468
  41. Park YM, Chung YC, Lee SH, et al. Weight gain associated with the α2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet. 2006;141:394–397
  42. Mäestu J, Allik J, Merenäkk L, et al. Associations between an α2a adrenergic receptor gene polymorphism and adolescent personality. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:418–423
  43. Camilleri CE, Carlson PJ, Camilleri M, et al. A study of candidate genotypes associated with dyspepsia in a US community. Am J Gastroenterol. 2006;101:581–592
  44. Ricca V, Nacmias B, Cellini E, et al. 5-HT2A receptor gene polymorphism and eating disorders. Neurosci Lett. 2002;323:105–108
  45. Aubert R, Betoulle D, Herbeth B, et al. 5-HT2A receptor gene polymorphism is associated with food and alcohol intake in obese people. Int J Obes Relat Metab Disord. 2000;24:920–924
  46. Westberg L, Bah J, Rastam M, et al. Association between a polymorphism of the 5-HT2C receptor and weight loss in teenage girls. Neuropsychopharmacology. 2002;26:789–793

 Supported in part by National Institutes of Health grants RO1 DK 67071 and K24 DK 02638 (to M.C.); by NIH grant RR024150, which supports the Mayo Clinical Research Unit; and, for DEXA measurements, by Public Health Service grant DK50456, which funds the Minnesota Obesity Center.

 Registration number of clinical trial at Clinical Trials.gov: NCT 00433641.

 Conflicts of interest: The authors have no conflicts of interest to disclose.

PII: S0016-5085(08)01317-6

doi: 10.1053/j.gastro.2008.07.009

Gastroenterology
Volume 135, Issue 4 , Pages 1142-1154 , October 2008

Article Tools

* Image Usage & Resolution